Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

24

Revenue 2017

Eylea

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Eylea was produced by Bayer.

Eylea growth closes the gap with Lucentis

Eylea growth closes the gap with Lucentis Bayer/Regeneron’s drug eye disease drug set for blockbuster status.  . Bayer and Regeneron's eye disease therapy Eylea is on course to break into the blockbuster club this year, after ... Armed with new indications such as diabetic macular edema (DME),

Trials of Roche's new blindness candidate now underway

Trials of Roche's new blindness candidate now underway While multiple therapies exist for wet AMD - Lucentis competes in the market with Bayer's Eylea (aflibercept) as well as off-label use of Roche's cancer drug Avastin (bevacizumab) - there

Top biotech firms saw sales jump in 2014

Top biotech firms saw sales jump in 2014 Dion explains: “Regeneron's sales grew by 34% in 2014, as the company continued its commercialisation of [eye disease drug] Eylea (afilibercept) to markets outside the US, including for the treatment

The BMJ weighs in on Avastin/Lucentis debate

The BMJ weighs in on Avastin/Lucentis debate Currently, General Medical Council guidance and European drug licensing laws say that Lucentis (ranibizumab), developed by Novartis and Roche, and Bayer/Regeneron's Eylea (aflibercept) - that are both approved to treat ... ahead of Lucentis and Eylea for

Bayer's Eylea cleared for wider use in Europe

Bayer's Eylea cleared for wider use in Europe The European Commission has approved Eylea (aflibercept) for the treatment of patients with macular oedema secondary to retinal vein occlusion. ... Eylea is being co-developed by Bayer and Regeneron, with Bayer holding exclusive marketing rights to the

[ Previous 5 results ] 2 3 4 5 6 7 8 9 10 11 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics